Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is 33.82% higher on its value in year-to-date trading and has touched a low of $769.19 and a high of $1161.21 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The REGN stock was last observed hovering at around $1156.86 in the last trading session, with the day’s gains setting it 18.47%.
Currently trading at $1175.33, the stock is 8.05% and 10.61% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.57 million and changing 1.60% at the moment leaves the stock 23.79% off its SMA200. REGN registered 45.84% gain for a year compared to 6-month gain of 24.00%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 8.26% loss in the last 1 month and extending the period to 3 months gives it a 20.15%, and is 5.57% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.22% over the week and 2.55% over the month.
Regeneron Pharmaceuticals, Inc. (REGN) has around 13450 employees, a market worth around $129.54B and $13.49B in sales. Current P/E ratio is 31.13 and Fwd P/E is 24.13. Profit margin for the company is 32.04%. Distance from 52-week low is 52.80% and 1.22% from its 52-week high. The company has generated returns on investments over the last 12 months (13.98%).
Regeneron Pharmaceuticals, Inc. quarterly earnings per share for the current quarter are estimated at 11.85 with sales reaching $3.66B over the same period.The EPS is expected to grow by 2.90% this year, but quarterly earnings will post 8.10% year-over-year. Quarterly sales are estimated to grow 8.80% in year-over-year returns.
1902.0 institutions hold shares in Regeneron Pharmaceuticals, Inc. (REGN), with institutional investors hold 90.95% of the company’s shares. The shares outstanding are 107.60M, and float is at 106.29M with Short Float at 1.89%. Institutions hold 89.56% of the Float.
The top institutional shareholder in the company is FMR LLC with over 10.79 million shares valued at $$10.39 billion. The investor’s holdings represent 10.0131 of the REGN Shares outstanding. As of 2024-03-31, the second largest holder is VANGUARD GROUP INC with 8.93 million shares valued at $$8.6 billion to account for 8.2841 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 8.57 million shares representing 7.9487 and valued at over $$8.25 billion, while JPMORGAN CHASE & CO holds 7.1681 of the shares totaling 7.73 million with a market value of $$7.44 billion.
Regeneron Pharmaceuticals, Inc. (REGN) Insider Activity
Regeneron Pharmaceuticals, Inc. disclosed in a document filed with the SEC on Aug 14 ’24 that MURPHY ANDREW J (EVP Research) sold a total of 6,363 shares of the company’s common stock. The trade occurred on Aug 14 ’24 and was made at $1153.15 per share for $7.34 million. Following the transaction, the insider now directly holds 48306.0 shares of the REGN stock.
Still, SEC filings show that on Aug 15 ’24, Bassler Bonnie L (Director) Proposed Sale 756 shares at an average price of $1170.00 for $0.88 million. The insider now directly holds shares of Regeneron Pharmaceuticals, Inc. (REGN).
